Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: A One-year Prospective Study

2008 ◽  
Vol 145 (2) ◽  
pp. 249-256.e2 ◽  
Author(s):  
Ziad F. Bashshur ◽  
Zeina A. Haddad ◽  
Alexandre Schakal ◽  
Rola F. Jaafar ◽  
Marc Saab ◽  
...  
2009 ◽  
Vol 148 (1) ◽  
pp. 59-65.e1 ◽  
Author(s):  
Ziad F. Bashshur ◽  
Zeina A. Haddad ◽  
Alexandre R. Schakal ◽  
Rola F. Jaafar ◽  
Alain Saad ◽  
...  

2021 ◽  
Author(s):  
Sankha Amarakoon ◽  
Jose P Martinez-Ciriano ◽  
Seerp Baarsma ◽  
L Ingeborgh van den Born ◽  
Tom Missotten

Introduction: Treatment of exudative age-related macular degeneration (ARMD) has shifted to pro re nata and treat-extend-stop strategies. However, a rational discontinuation strategy is lacking. To develop such a strategy, it is important to determine choroidal neovascularization (CNV) recurrence rates after anti-VEGF treatment is discontinued. Methods: This prospective, single-centre clinical trial enrolled 191 patients with exudative ARMD. Patients were randomly assigned to receive intravitreal bevacizumab injections every 4, 6, or 8 weeks for one year. CNV activity was determined in the 157 patients who completed the one-year treatment regimen. Patients with inactive CNV were then followed for signs of CNV reactivation. Results: After one year of treatment, 66 (42%) of the 157 patients still had signs of persistent active CNV. Of the remaining 91 (58%) patients, 61 (67%) needed retreatment for active CNV within the first year after discontinuation of treatment (mean 4.28±0.29 months). CNV was reactivated in 50 (80%) of the 61 patients within 6 months after their final treatment for CNV. Conclusion: Based on quiescent disease, anti-VEGF therapy was discontinued in 58% of patients after they received bevacizumab injections every 4, 6, or 8 weeks for one year; 67% showed reactivated CNV within the year after discontinuation. The high reactivation rate of CNV shown in this study, should help clinicians develop rational discontinuation protocols.


2021 ◽  
pp. 247412642199705
Author(s):  
Halward M.J. Blegen ◽  
Samuel D. Hobbs ◽  
Reggie Taylor ◽  
Andrew L. Plaster ◽  
Paul M. Drayna

Purpose: Optical coherence tomography (OCT) is useful in diagnosing and monitoring retinal pathology such as age-related macular degeneration, diabetic macular edema (DME), central serous chorioretinopathy, and epiretinal membrane, among others. This study compared the ability of horizontal (H) 25-, 13-, and 7-cut macular OCT vs 24-, 12-, and 6-cut radial (R) macular OCT in identifying various macular pathology. Methods: This was a prospective study of 161 established patients evaluated at Wilford Hall Eye Center Retina Clinic between September and October of 2019. Pathology included age-related macular degeneration, central serous chorioretinopathy, DME, and epiretinal membrane, among others. Patients obtained 25-, 13-, and 7-cut H raster OCT as well as 24-, 12-, and 6-cut R OCT. Primary outcomes were sensitivity in detecting macular fluid and each macular abnormality. Results: The 24-cut radial (R24) OCT equally or out-performed the H25 (horizontal 25-cut OCT) in detecting macular fluid across all pathological groups. Generally, a higher number of cuts correlated with better detection of fluid. In detecting any macular abnormalities, H25, R24, and R12 had 100% sensitivity. R6 OCT had near 100% sensitivity across all groups, except for DME (95%). Overall, R OCT had better sensitivity (0.960) than H OCT (0.907) in detecting macular pathology. Conclusions: R outperformed H macular OCT in detecting fluid and other abnormalities. Clinically, both scanning patterns can be used by ophthalmologists in diagnosis and management of commonly encountered macular diseases. Technicians may be able to use a variety of these scans to screen for pathology prior to physician evaluation.


Ophthalmology ◽  
2010 ◽  
Vol 117 (2) ◽  
pp. 298-302 ◽  
Author(s):  
Donald S. Fong ◽  
Peter Custis ◽  
Jennifer Howes ◽  
Jin-Wen Hsu

Sign in / Sign up

Export Citation Format

Share Document